![Amy Chappell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Chappell
Directeur/Membre du Conseil chez
BIOVIE INC.
Fortune : 1 105 $ au 30/09/2026
Profil
Amy S.
Chappell is currently an Independent Director at BioVie, Inc. since 2025 and Chief Medical Officer at Solaxa, Inc. since 2024.
Formerly, Dr. Chappell was Chief Medical Officer at Climb Bio, Inc. from 2020 to 2021.
Education includes undergraduate studies at Antioch College and a doctorate from The Indiana University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOVIE INC. CLASS A 0,01 % | 31/08/2026 | 727 ( 0,01 % ) | 1 105 $ | 30/09/2026 |
Postes actifs de Amy Chappell
| Sociétés | Poste | Début |
|---|---|---|
| BIOVIE INC. | Directeur/Membre du Conseil | 22/07/2025 |
Anciens postes connus de Amy Chappell
| Sociétés | Poste | Fin |
|---|---|---|
| CLIMB BIO, INC. | Directeur Technique/Scientifique/R&D | 31/12/2021 |
Formation de Amy Chappell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
20
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Antioch College
 Antioch College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Indiana University School of Medicine
 The Indiana University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
